{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:16:21Z","timestamp":1776824181721,"version":"3.51.2"},"reference-count":34,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>\n                      Guideline-based therapy (GBT) of\n                      <jats:italic>Mycobacterium abscessus<\/jats:italic>\n                      (MAB) lung disease (LD) achieves a sputum culture conversion rate in \u223c35% of patients. The \u03b2-lactam antibiotics, imipenem and cefoxitin, are the cornerstone of GBT. However, a 1-h half-life means multiple infusions per day, which is difficult for months-long therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>As an alternative, we tested ceftaroline\u2013avibactam, with a 3-h half-life, in the hollow-fibre model system of MAB-LD (HFS-MAB). Eight ceftaroline\u2013avibactam exposures were administered twice daily based on human intrapulmonary pharmacokinetics. Next, we compared GBT (cefoxitin\u2013clarithromycin\u2013amikacin) to standard-dose and to high-dose ceftaroline\u2013avibactam\u2013tigecycline\u2013moxifloxacin regimens, in the HFS-MAB, mimicking the intrapulmonary pharmacokinetics of all drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Ceftaroline\u2013avibactam maximal microbial kill was 0.72 log\n                      <jats:sub>10<\/jats:sub>\n                      colony-forming units (CFUs) per millilitre below day 0 burden (stasis). The ceftaroline pharmacokinetic\u2013pharmacodynamic parameter linked to microbial kill and anti-microbial resistance was 0\u201324-h area under the concentration\u2013time curve (AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      ) to minimum inhibitory concentration. GBT killed 1.21 \u00b1 0.25 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU\/mL versus 0.45 \u00b1 0.42 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU\/mL below stasis for high-dose ceftaroline combination (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.20). In combination regimens, proportion of the ceftaroline-resistant subpopulation was 41.22 \u00b1 13.11 times lower than the cefoxitin-resistant subpopulation (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Ceftaroline\u2013avibactam administered twice a day would be an adequate replacement for the four-times-a-day cefoxitin treatments for MAB-LD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/ijtldopen.25.0173","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:30:52Z","timestamp":1757651452000},"page":"519-526","source":"Crossref","is-referenced-by-count":3,"title":["Ceftaroline pharmacokinetics\/pharmacodynamics in the hollow-fibre model of\n                    <i>Mycobacterium abscessus<\/i>\n                    lung disease"],"prefix":"10.5588","volume":"2","author":[{"given":"B.E.","family":"Ferro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2026011502141354000_2.9.519.1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241"},{"key":"2026011502141354000_2.9.519.2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-15"},{"issue":"6","key":"2026011502141354000_2.9.519.3","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiae601","article-title":"Imipenem pharmacokinetics\/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung disease","volume":"231","author":"Singh","year":"2024","journal-title":"J Infect Dis"},{"key":"2026011502141354000_2.9.519.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01206-17"},{"key":"2026011502141354000_2.9.519.5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01977"},{"key":"2026011502141354000_2.9.519.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02821-15"},{"key":"2026011502141354000_2.9.519.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106847"},{"key":"2026011502141354000_2.9.519.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz523"},{"key":"2026011502141354000_2.9.519.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03112-15"},{"key":"2026011502141354000_2.9.519.10","unstructured":"Food and Drug Administration . TEFLARO\u00ae (ceftaroline fosamil) injection for intravenous (IV) use. Silver Spring, MD, USA: FDA, 2010, pp. 1-22."},{"key":"2026011502141354000_2.9.519.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02282-15"},{"key":"2026011502141354000_2.9.519.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00990-16"},{"key":"2026011502141354000_2.9.519.13","unstructured":"Paratek Pharmaceuticals, Inc . Paratek pharmaceuticals announces positive top-line data from phase 2b study of oral omadacycline (OMC) in nontuberculous Mycobacterial (NTM) abscessus pulmonary disease. Globenewswire, November 8, 2024."},{"key":"2026011502141354000_2.9.519.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00098-20"},{"key":"2026011502141354000_2.9.519.15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt410"},{"key":"2026011502141354000_2.9.519.16","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0047"},{"key":"2026011502141354000_2.9.519.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(03)00126-3"},{"key":"2026011502141354000_2.9.519.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02755-15"},{"issue":"2","key":"2026011502141354000_2.9.519.19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40121-013-0010-x","article-title":"Ceftaroline fosamil: a brief clinical review","volume":"2","author":"Shirley","year":"2013","journal-title":"Infect Dis Ther"},{"key":"2026011502141354000_2.9.519.20","unstructured":"CLSI . Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. 3rd ed. Wayne, PA, USA: Clinical and Laboratory Standards Institute, 2018."},{"key":"2026011502141354000_2.9.519.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.02.007"},{"key":"2026011502141354000_2.9.519.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05546-11"},{"key":"2026011502141354000_2.9.519.23","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"2026011502141354000_2.9.519.24","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"2026011502141354000_2.9.519.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy609"},{"key":"2026011502141354000_2.9.519.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"2026011502141354000_2.9.519.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00829-13"},{"issue":"2","key":"2026011502141354000_2.9.519.28","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1093\/infdis\/jiad545","article-title":"Ceftriaxone efficacy for Mycobacterium avium complex lung disease in the hollow fiber and translation to sustained sputum culture conversion in patients","volume":"230","author":"Deshpande","year":"2023","journal-title":"J Infect Dis"},{"issue":"3","key":"2026011502141354000_2.9.519.29","doi-asserted-by":"crossref","first-page":"107204","DOI":"10.1016\/j.ijantimicag.2024.107204","article-title":"Ertapenem\u2019s therapeutic potential for Mycobacterium avium lung disease in the hollow fiber model","volume":"64","author":"Deshpande","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026011502141354000_2.9.519.30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac068"},{"key":"2026011502141354000_2.9.519.31","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02895-18"},{"key":"2026011502141354000_2.9.519.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05080-14"},{"key":"2026011502141354000_2.9.519.33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1701102"},{"key":"2026011502141354000_2.9.519.34","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx306"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.25.0173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:23:38Z","timestamp":1768472618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.25.0173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.5588\/ijtldopen.25.0173"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.25.0173","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}